ImmunityBio (IBRX) Stock Price, News & Analysis

Company Overview

ImmunityBio, Inc. is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies.

Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas.

Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.

Key Stats

• Today's Range: $7.23 to $7.65
• 50-Day Range: $6.66 to $9.40
• 52-Week Range: $1.95 to $12.43
• Volume: 15.53 million shs
• Average Volume: 14.05 million shs
• Market Capitalization: $7.88 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.20
• Consensus Rating: Moderate Buy

ImmunityBio Stock Analysis - MarketRank™

ImmunityBio scored higher than 58% of companies evaluated by MarketBeat, and ranked 468th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ImmunityBio has a consensus price target of $14.20, representing about 88.8% upside from its current price of $7.52.

Amount of Analyst Coverage

ImmunityBio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunityBio are expected to grow in the coming year, from ($0.31) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunityBio is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunityBio is -8.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

41.53% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 10.57, which indicates bearish sentiment.

Change versus previous month

Short interest in ImmunityBio has recently decreased by 3.88%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunityBio does not currently pay a dividend.

Dividend Growth

ImmunityBio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.48

News Sentiment

ImmunityBio has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for ImmunityBio this week, compared to 11 articles on an average week.

Search Interest

Only 69 people have searched for IBRX on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

MarketBeat Follows

26 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 53% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunityBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

69.48% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.58% of the stock of ImmunityBio is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/30/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IBRX
• CIK: 1326110
• Web: immunitybio.com
• Phone: (858) 633-0300
• Fax: N/A
• Employees: 590
• Year Founded: 2014

Price Target and Rating

• Average Price Target for ImmunityBio: $14.20
• High Price Target: $23.00
• Low Price Target: $9.00
• Potential Upside/Downside: +88.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$351.40 million
• Net Margins: -606.15%
• Pretax Margin: -606.12%
• Return on Equity: N/A
• Return on Assets: -59.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.67
• Quick Ratio: 6.66

Sales & Book Value

• Annual Sales: $113.29 million
• Price / Sales: 69.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.83) per share
• Price / Book: -9.06

Miscellaneous

• Outstanding Shares: 1,047,350,000
• Free Float: 319,652,000
• Market Cap: $7.88 billion
• Optionable: Optionable
• Beta: 0.02